Published in Eur Urol on February 01, 2012
Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. J Clin Oncol (2015) 2.71
Nonparametric Bounds and Sensitivity Analysis of Treatment Effects. Stat Sci (2014) 0.88
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 0.86
Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res (2014) 0.84
Crucial role of androgen receptor in vascular H2S biosynthesis induced by testosterone. Br J Pharmacol (2014) 0.81
The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol (2015) 0.79
The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol (2016) 0.78
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol (2015) 0.77
Androgen receptor (AR) in cardiovascular diseases. J Endocrinol (2016) 0.77
Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. Cancer Med (2016) 0.75
Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease? Can Urol Assoc J (2017) 0.75
Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. Can Urol Assoc J (2017) 0.75
Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing? Eur Urol (2012) 0.75
Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf (2015) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care (1993) 9.72
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics (1998) 8.48
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation (2004) 7.30
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med (2009) 5.82
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med (2010) 4.52
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer (2007) 3.92
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. Epidemiology (2011) 2.61
Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J Am Med Assoc (1950) 2.59
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol (2010) 2.56
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) (2003) 2.07
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res (2009) 1.89
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol (2010) 1.62
Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation (2010) 1.62
[Androgen deprivation for advanced prostate cancer]. Urologe A (2008) 1.14
Effects of androgens on haemostasis. Maturitas (1996) 1.13
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst (2009) 1.11
Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm (2005) 1.06
Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res (2007) 0.99
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol (2007) 0.89
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Improving the management of chronic disease at community health centers. N Engl J Med (2007) 7.88
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med (2008) 5.27
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation (2007) 4.58
Long-Term Outcomes of Abdominal Aortic Aneurysm in the Medicare Population. N Engl J Med (2015) 4.41
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol (2008) 4.23
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol (2010) 3.78
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol (2013) 3.70
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol (2012) 2.79
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
Access to specialty care and medical services in community health centers. Health Aff (Millwood) (2007) 2.63
Variation in patient-sharing networks of physicians across the United States. JAMA (2012) 2.59
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst (2011) 2.48
Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol (2012) 2.37
The costs and potential savings associated with nursing home hospitalizations. Health Aff (Millwood) (2007) 2.33
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst (2010) 2.18
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Relationship between quality of care and negligence litigation in nursing homes. N Engl J Med (2011) 2.15
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Trends in mammography screening rates after publication of the 2009 US Preventive Services Task Force recommendations. Cancer (2013) 2.14
Evidence-based risk communication: a systematic review. Ann Intern Med (2014) 2.14
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol (2011) 2.09
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol (2014) 2.08
Comparison of outpatient narcotic prescribing patterns after minimally invasive versus retropubic and perineal radical prostatectomy. J Urol (2011) 2.05
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Thirty-day mortality and late survival with reinterventions and readmissions after open and endovascular aortic aneurysm repair in Medicare beneficiaries. J Vasc Surg (2010) 2.02
Proximity to food establishments and body mass index in the Framingham Heart Study offspring cohort over 30 years. Am J Epidemiol (2011) 2.00
Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (2010) 2.00
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Thrombosed external hemorrhoids: outcome after conservative or surgical management. Dis Colon Rectum (2004) 1.94
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys (2013) 1.89
The role of primary care physicians in cancer care. J Gen Intern Med (2009) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2009) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer (2012) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Explaining racial differences in prostate cancer mortality. Cancer (2012) 1.82
Methods used to streamline the CAHPS Hospital Survey. Health Serv Res (2005) 1.79
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Medicare Part D and nursing home residents. J Am Geriatr Soc (2007) 1.74
Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol (2009) 1.74
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Is spending more always wasteful? The appropriateness of care and outcomes among colorectal cancer patients. Health Aff (Millwood) (2008) 1.70
Mapping physician networks with self-reported and administrative data. Health Serv Res (2011) 1.70
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol (2008) 1.69
Medical oncologists' perceptions of financial incentives in cancer care. J Clin Oncol (2012) 1.69
National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med (2010) 1.67
Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer (2009) 1.66
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64